Showing results (191-200 of 682) with videos related to
Sort By:
Pageof 69
Clinical Lymphoma, Myeloma & Leukemia|March 8, 2022
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST StudyAaron T Gerds, Roger M Lyons, Philomena Colucci, et al.Blood|May 31, 2011
Comparison of thalidomide and lenalidomide as therapy for myelofibrosisElias Jabbour, Deborah Thomas, Hagop Kantarjian, et al.Cancer|October 6, 2010
Experimental therapeutics for patients with myeloproliferative neoplasiasMeetu Agrawal, Ravin J Garg, Jorge Cortes, et al.Expert Review of Hematology|October 3, 2013
Practical management of patients with myelofibrosis receiving ruxolitinibClaire Harrison, Ruben Mesa, David Ross, et al.Cancer|February 28, 2019
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemiaChristopher B Benton, Prajwal C Boddu, Courtney D DiNardo, et al.Journal of Clinical Microbiology|January 29, 2011
Disseminated fusariosis occurring in two patients despite posaconazole prophylaxisPrithviraj Bose, Hiral D Parekh, Jennifer L Holter, et al.Journal of Experimental Pharmacology|August 31, 2016
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitorJack W Singer, Suliman Al-Fayoumi, Haiching Ma, et al.Leukemia Research|June 10, 2017
Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcomePreetesh Jain, Sa Wang, Keyur P Patel, et al.The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.Blood|July 5, 2003
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AMLElihu H Estey, Peter F Thall, Xuemei Wang, et al.Pageof 69